Research article summary (published 29 Apr 2009):

Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting.

Full Abstract

Although symptoms of attention-deficit/ hyperactivity disorder (ADHD) are certainly most visible in children, the syndrome persists into adolescence in 40% to 70% of cases and into adulthood in 50% or more of cases. Accurate recognition of the disorder is clouded by the frequent presence of psychiatric comorbidities. Contributing to these challenges, managed care providers in primary care are often inexperienced in identifying and treating ADHD in adults because of a lack of formalized training. As such, special consideration must be given to each individual age group and includes identifying common clinical presentations, characterizing the disorder and its comorbidities, applying validated rating scales as screening and treatment outcome measures, and individually assessing patients' optimal response to determine the best course of therapy. Pharmacotherapy is often initiated to target ADHD symptoms with either a stimulant medication or nonstimulants. In addition, behavioral interventions are often applied to treat comorbidities and associated impairments of ADHD.

Author information

Author/s: Jensen, Peter S (PS);

Affiliation: The REACH Institute, 450 Seventh Ave, Ste 1107, New York, NY 10123, USA. peter.jensen(-atsign-)thereachinstitute.org

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: The American journal of managed care (Am J Manag Care), published in United States. (Language: eng)

Reference: 2009-May; vol 15 (issue 5 Suppl) : pp S129-40

Dates: Created 2009/07/15; Completed 2009/10/08;

PMID: 19601688, status: MEDLINE (last retrieval date: 10/8/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adrenergic Uptake Inhibitors - therapeutic use Attention Deficit Disorder with Hyperactivity - diagnosis; drug therapy Central Nervous System Stimulants - therapeutic use Dextroamphetamine - therapeutic use Diagnostic and Statistical Manual of Mental Disorders

Dopamine Uptake Inhibitors - therapeutic use Humans Managed Care Programs Methylphenidate - therapeutic use Propylamines - therapeutic use

Associated Chemicals: Adrenergic Uptake Inhibitors (0) ; Central Nervous System Stimulants (0) ; Dopamine Uptake Inhibitors (0) ; Propylamines (0) ; Methylphenidate (113-45-1) ; Dextroamphetamine (51-64-9) ; atomoxetine (83015-26-3)

Related articles

These are the highest related articles currently in the database:

• Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE). 12 Feb 2008
• Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. 30 Oct 2008
• Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. 30 Mar 2008
• Improving decision making in the treatment of ADHD. 30 May 2008
• Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. 15 Nov 2007
• Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary. 30 Jan 2006
• Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. 30 May 2007
• Update on drugs for hyperactivity in childhood. 29 Apr 2007
• Atomoxetine. 29 Jun 2006
• Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. 30 Mar 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.